



# Experience summary

# Summary of services

Abacus International is an independent consultancy specialising in health economics/modelling, health technology assessment, systematic review, medical writing and market access. Our services cover a wide range of core deliverables throughout the product lifecycle.

## Global Health Technology Assessments (HTA)

- Development of economic model
- Preparation of submission document
- Liaison with HTA body
- Tracking HTA decisions

## Systematic Literature Reviews

- Formulation/Development of research question, study protocol & search strategy
- Data extraction
- Qualitative reports
- Meta-analysis / Indirect and mixed treatment comparisons
- Peer reviewed publications

## Health Economics

- Development of health economic strategy
- Economic models
- Model training programme

## Payer Communications

- Global value dossiers
- Budget impact models
- Interactive sales tools
- Formulary packs
- Key value summaries
- Publications / posters

## Data Synthesis and Evaluation

- Retrospective and prospective data analysis
- Advisory boards
- Healthcare needs assessments
- Patient registries, audits and online surveys

Active clients | 1

Health Technology Assessments | 2

Systematic Literature Reviews | 3

Value Dossiers | 4

Models | 5

Publications | 6

Contacts | 7

# 1 | Active clients

Abacus International's extensive client list features pharmaceutical and medical device companies, located throughout Europe, North America and Asia.

Abbott

Alexion

ALK-Abello

Allergan

Amgen

Astellas

Astra Zeneca

Basilea Pharmaceuticals

Bayer

Boehringer Ingelheim

Bristol-Myers Squibb

Codman

Daiichi-Sankyo

Deloitte

Eli Lilly

Enturia

Ethicon Endosurgery

Ferring

Finceramica

Galderma

Galen

GE Healthcare

Genzyme

Gilead

GlaxoSmithKline

Ipsen

IS Pharma

Johnson & Johnson



Medline Industries

Medtronic

Merck & Co

Merck Serono

Molnlycke

Movetis

Mundipharma

Napp

Novartis

Novo Nordisk

Nutricia

Otsuka

Pfizer

Procter & Gamble

Roche

Sanofi Aventis

Sanofi Pasteur

Servier

Shire

Stryker

Sucampo

Takeda

UCB

Wyeth

“We love the work and the way that nothing is impossible!” - Allergan

“When performing a systematic review for us, Abacus went beyond our usual expectations” - Boehringer Ingelheim

“A great approach to our needs. I have already recommended Abacus International to other potential customers.” - Gilead

bright minds, brilliant outcomes

## 2 | Health Technology Assessments

### NICE submissions

Abdominal aortic aneurysm - endovascular stent-grafts  
Alzheimer's disease - donepezil, rivastigmine and galantamine  
Asthma (older children) - inhaler devices  
Asthma (in adults) - corticosteroids  
Asthma (in children) - corticosteroids  
Attention deficit hyperactivity disorder - methylphenidate, atomoxetine and dexamfetamine (review)  
Bradycardia - dual chamber pacemakers  
Colorectal cancer - capecitabine and tegafur uracil  
Coronary imaging - myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction  
Crohn's disease - infliximab  
Diabetes - insulin pump therapy  
Diabetes - insulin pump therapy (review)  
Diabetes (type 2) - rosiglitazone  
Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide  
Growth failure in children - human growth hormone review  
Hearing disability - hearing aids  
Hepatitis B - adefovir dipivoxil and pegylated interferon alpha-2a  
Hepatitis B - tenofovir disoproxil fumarate  
Hepatitis C - pegylated interferons, ribavirin and alfa interferon  
Hernia (inguinal) - laparoscopic surgery  
Hip disease - metal on metal resurfacing  
Menstrual bleeding - fluid-filled thermal balloon and microwave endometrial ablation  
Multiple sclerosis - beta interferon and glatiramer acetate  
Pain (chronic neuropathic or ischaemic) - spinal cord stimulation  
Pregnancy - routine anti-D prophylaxis for RhD-negative women  
Psoriasis - efalizumab and etanercept  
Renal failure - home versus hospital haemodialysis  
Rheumatoid arthritis - adalimumab, etanercept and infliximab  
Rheumatoid arthritis - etanercept and infliximab  
Schizophrenia - atypical antipsychotics  
Tooth decay - HealOzone

## SMC submissions

Adefovir dipivoxil (Hepsera<sup>®</sup>) - chronic hepatitis B  
Aripiprazole (Abilify<sup>®</sup>) - schizophrenia  
Bivalirudin (Angiox<sup>®</sup>) - percutaneous coronary intervention  
Cilostazol (Pletal<sup>®</sup>) - improved pain-free walking distance in patients with intermittent claudication  
Clostridium botulinum toxin type A (Botox<sup>®</sup>) - post-stroke spasticity  
Conjugated oestrogen medroxyprogesterone (Premique Low Dose<sup>®</sup>) - hormone replacement therapy  
Daptomycin (Cubicin<sup>®</sup>) - complicated skin and soft-tissue infections  
Degarelix (Firmagon<sup>®</sup>) – advance prostate cancer  
Diboterminalfa (InductOs<sup>®</sup>) - acute tibia fractures  
Efalizumab (Raptiva<sup>®</sup>) - moderate to severe chronic plaque psoriasis  
Efavirenz, emtricitabine, tenofovir disoproxil fumarate (Atripla<sup>®</sup>) - HIV  
Emtricitabine/tenofovir disoproxil (Truvada<sup>®</sup>) - HIV  
Enoxaparin (Clexane<sup>®</sup>) – myocardial infarction with ST-segment elevation  
Erdosteine (Erdotin<sup>®</sup>) - acute exacerbations of chronic bronchitis in adults  
Estradiol/drospirenone (Angeliq<sup>®</sup>) - hormone replacement therapy  
Fentanyl buccal tablets (Effentora<sup>®</sup>) - breakthrough pain in adults with cancer  
Interferon alfa 2b (Viraferon<sup>®</sup>) - paediatric hepatitis C  
Levetiracetam (Keppra<sup>®</sup>) - juvenile myoclonic epilepsy in adolescents and adults  
Levetiracetam (Keppra<sup>®</sup>) - partial onset seizures in adults with epilepsy  
Levetiracetam (Keppra<sup>®</sup>) - partial onset seizures in children with epilepsy  
Levetiracetam (Keppra<sup>®</sup>) - primary generalised tonic-clonic seizures in adults and adolescents with epilepsy  
Lidocaine (Versatis<sup>®</sup>) - neuropathic pain, post-herpetic neuralgia  
Medicated sponge (TachoSil<sup>®</sup>) - haemostasis in kidney surgery  
Medicated sponge (TachoSil<sup>®</sup>) - haemostasis in liver surgery  
Mesalazine (Asacol<sup>®</sup>) - ulcerative colitis  
Metformin hydrochloride (Glucophage SR<sup>®</sup>) - type 2 diabetes  
Methylphenidate (Equasym XL<sup>®</sup>) - attention deficit hyperactivity disorder  
Moxifloxacin (Avelox<sup>®</sup>) - acute exacerbations of chronic bronchitis  
Moxifloxacin (Avelox<sup>®</sup>) - community acquired pneumonia  
Oxycodone/naloxone (Targinact<sup>®</sup>) – severe pain

List continues overleaf

bright minds, brilliant outcomes

## 2 | Health Technology Assessments

### SMC submissions (continued)

Palonosetron (Aloxi®) - prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy  
Posaconazole (Noxafil®) – specific invasive fungal infections  
Rabbit anti-human thymocyte immunoglobulin solution (Thymoglobuline®) - prevention of graft rejection in renal transplantation  
Rotigotine (Neupro®) - advanced Parkinson's disease  
Rotigotine (Neupro®) - early Parkinson's disease  
Rotigotine (Neupro®) - restless legs syndrome  
Saxagliptin (Onglyza®) – type 2 diabetes  
Solifenacin (Vesicare®) - urge incontinence and/or increased urinary frequency  
Sorafenib (Nexavar®) - advanced renal cell carcinoma  
Tacrolimus (Prograf®) - prophylaxis of transplant rejection in heart allograft recipients  
Tacrolimus ointment (Protopic®) – moderate to severe atopic dermatitis  
Tenofovir disoproxil fumarate (Viread®) - chronic hepatitis B in adults  
Testosterone gel (Testim®) - adult male hypogonadism  
Testosterone injection (Nebido®) - adult male hypogonadism  
Testosterone patch (Intrinsa®) - hypoactive sexual desire disorder  
Zoledronic acid (Zometa®) - bone cancer

### AWMSG submissions

Emtricitabine/tenofovir (Truvada®) - HIV  
Emtricitabine (Emtriva®) - HIV  
Enoxaparin (Clexane®) – myocardial infarction with ST-segment elevation  
Sorafenib (Nexavar®) – advanced renal cell carcinoma  
Tacrolimus (Advagraf®) - prevention of rejection in kidney/liver transplant recipients  
Tenofovir (Viread®) - chronic hepatitis B in adults

### Other HTA groups

#### TLV – Sweden

Hormone replacement therapy  
Moderate to severe vasomotor symptoms

#### CDR – Canada

Renal disease  
Chronic hepatitis B

#### JCVI – UK

Herpes zoster  
Rotavirus

#### PBAC – Australia

Chronic hepatitis B

## 3 | Systematic Literature Reviews

### Systematic literature reviews and meta analyses

Alzheimer's disease: control of behavioural and psychological symptoms

Alzheimer's disease and/or dementia: cholinesterase inhibitors in real-world setting

Alzheimer's disease: nutritional intervention on symptom control and disease progression

Amino-acid based formulas in relieving the symptoms of cow's milk allergy

Atopic eczema: current therapeutic interventions

Atrial fibrillation: management strategies

Atrial fibrillation: sequelae of poor anticoagulation control

Cardiac rehabilitation

Chronic hepatitis C: pegylated interferon alpha 2b (viraferonPRG®) plus ribavirin (rebetol®)

Chronic lymphocytic leukaemia (CLL), relapsed

Chronic lymphocytic leukaemia (CLL), relapsed, fludarabine-resistant

Chronic obstructive pulmonary disease (COPD)

Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer

Enteral nutritional support and use of diabetes-specific formulae for patients with diabetes mellitus

Enteral nutritional support in prevention and treatment of pressure ulcers

Enteral nutritional support: use of fibre supplements

Fibromyalgia: current therapeutic interventions

Follicular lymphoma: maintenance therapies

Gastric banding for bariatric surgery

Gonadotropin use in in vitro fertilisation

Head & neck cancer: epidemiology, costs, and current interventions

Hip fractures: surgical management

# 3 | Systematic Literature Reviews

## Systematic literature reviews and meta analyses

Idiopathic (immune) thrombocytopenic purpura (ITP)

Liposomal amphotericin B in neutropenia

Metastatic breast cancer: cross-resistance between third generation steroidal and non-steroidal aromatase inhibitors

Multi-nutrient oral supplements and tube feeding in maintenance dialysis

Neuropathic pain: current therapeutic interventions

Oral nutritional supplementation in the community setting

Overactive bladder (OAB): antimuscarinic therapy

Palliative care: resource utilisation

Pancreatic neuroendocrine tumours (PNET)

Peripheral sensitivity neuropathy (chemotherapy induced)

Primary open angle glaucoma (POAG) and ocular hypertension (OH): topical interventions

Smoking cessation therapies in smokers with co-morbid conditions

Type 2 diabetes: incretin therapy

Venous thromboembolism (VTE) prophylaxis in orthopaedic surgery

## 4 | Value Dossiers

Value dossiers and summaries	Key value messages	Economic evaluation	Region
Open tibial fractures Medtronic	✓	✓	Europe
Spinal fusion Medtronic	✓	✓	Europe
Overactive bladder Astellas	✓	✓	Europe
Chemotherapy induced nausea & vomiting Merck and Co.	✓	Partial	Global
Herpes Zoster Sanofi Pasteur MSD	✓	✓	Europe
Immunosuppression in renal transplantation Astellas	✓	✓	Europe
Restless legs syndrome UCB	✓	✓	Global
Parkinson's disease UCB	✓	✓	Global
Hypereosinophilic Syndrome (HES) GSK	✓	✓	Global
Drug eluting stents Medtronic	✓	✓	Global
Diabetes Abbott	✓	✓	Global
Conditions relating to short stature Novo Nordisk	✓	✓	Global
Paroxysmal nocturnal haemoglobinuria (PNH) Alexion	✓	✗	Global
COPD Boehringer Ingelheim	✓	✗	Global
Stents Abbott Vascular	✓	✗	Europe

bright minds, brilliant outcomes

# 5 | Models

We have developed over 100 health economic models across a wide range of therapeutic areas, including:

## **Cardiology**

Acute coronary syndromes  
Angina  
Angiography  
Arrhythmia  
CABG  
Coronary artery disease  
Cardiac resynchronisation therapy  
Chronic heart failure  
Deep vein thrombosis  
Hyperlipidemia  
Hypertension  
Implantable cardioverter defibrillators  
Myocardial infarction  
Pacemakers  
Statins  
Stroke

## **Infection and inflammation**

Crohn's disease  
Hepatitis B  
Hepatitis C  
HIV  
Influenza  
Irritable bowel syndrome  
Invasive fungal infections

Meningitis

MRSA

Osteoarthritis

Osteoporosis

Psoriasis - Atopic dermatitis

Rheumatoid arthritis

Primary immune deficiency

Septic shock

## **Metabolic**

Diabetes

Growth hormone deficiency

HRT

Hyperparathyroidism

Insulin pumps

Short for gestational age

## **Neurology**

ADHD

Alzheimer's disease

Depression

Juvenile cerebral palsy

Multiple sclerosis

Schizophrenia

Spasticity

Chronic neuropathic pain



## **Oncology**

Breast cancer  
Bladder tumour testing  
Bone metastases  
Cervical cancer  
Chemotherapy induced nausea  
& vomiting  
Colorectal cancer screening  
Glioblastoma  
Head and neck cancer  
Prostate cancer  
Renal cell carcinoma  
Skin cancer

## **Orthopaedic**

Hip fractures  
Hip resurfacing  
Osteoporosis  
Spinal fusions  
Tibia fractures

## **Respiratory**

Asthma  
Chronic bronchitis  
COPD

## **Urinary**

Bladder cancer

Overactive bladder  
Urinary tract infection

## **Other**

Cancer pain  
Cervical dystonia  
Chronic kidney disease  
Chronic pain  
Constipation  
Cranial implants  
Diarrhoea  
Dialysis services  
Glaucoma  
Impotence  
Infertility  
Liver transplantation  
Macular degeneration  
Macular oedema  
Needle-stick injury  
Nutrition  
Post-operative pain  
Renal transplantation  
Seasonal allergic rhinitis  
Smoking cessation  
Surgical adhesions  
Tooth decay  
Travel vaccinations

We have also developed several healthcare needs assessment models (HCNAs) in numerous therapeutic areas, including: dementia, diabetes and urge incontinence.

bright minds, brilliant outcomes

## 6 | Publications

### Cardiovascular

Barwell, Patel, Marelli, editors. Modelling the effect of diagnostic strategies in patients with suspected coronary artery disease (CAD) on capacity and productivity of coronary diagnostic facilities in the United Kingdom. ISPOR; 2008; Athens.

Duggan AK, Niziol CJ. Real-life treatment of hypertension in UK primary care: prescribing habits, results and adherence to clinical guidelines. *Br J Cardiol* 2003; 10 (Suppl 3): S3–7

Hayes P, Ryan J, Jensen M, Harrison L, Brasseur P, editors. Cost-effectiveness of endovascular aneurysm repair versus open surgical repair: acute infrarenal abdominal aortic aneurysm in an emergency setting; 2008.

Howard S. A survey measuring the impact of NICE guidance 49: The use of ultrasound locating devices for placing central venous catheters. *Abacus International Survey*, July 2004 ([www.nice.org.uk](http://www.nice.org.uk)) 2004

Menown I, Jacob A, Orme M, Gillard S. Clexane/Lovenox (enoxaparin) is a cost-effective adjunctive treatment to fibrinolysis for ST-elevation myocardial infarction (STEMI) compared with unfractionated heparin. *European Heart Journal* 2008; 29 (Abstract supplement):P3546, 568-569

Menown I, Montalescot G, Pal N, Fidler C, Orme M, Gillard S. Enoxaparin is a cost-effective adjunct to fibrinolytic therapy for ST-elevation myocardial infarction in contemporary practice. *Adv Ther.* 2010 Apr 23.


Mitchell S, Orme M, Eckert L, Reynolds M, editors. The effect of anti-arrhythmic drug therapy on all-cause and cardiovascular mortality in atrial fibrillation patients: a systematic review and meta-analysis. Presented at ISPOR 12th Annual European conference; 2009.

Ratcliffe A, Barwell T, Chambers M. Economic Evaluation of Diagnostic Strategies in Patients with Suspected Coronary Artery Disease (CAD) in the UK. In: *ISPOR 9th Annual European Congress*; 2006 28-31 October 2006; Denmark; 2006

Schachter M, Mitchell G, Niziol C, Abhyankar B. Antihypertensive efficacy of moxonidine in primary care: a 'real life' study. *Int J Clin Pract* 2003; 57(6): 479–82

Sullivan S, Orme M, Morais E, Mitchell S. A systematic review and meta-analysis of randomised clinical trials reviewing anti-arrhythmic drugs for the treatment of atrial fibrillation. Presented at ISPOR 12th Annual European conference; 2009.

Underwood S.R, Barwell T, Basu S, Chambers M, Zyczynski T, editors. An economic evaluation of myocardial perfusion scintigraphy in the diagnosis of coronary artery disease.



Walley T, Duggan AK, Haycox AR, Niziol CJ. Treatment for newly diagnosed hypertension: patterns of prescribing and antihypertensive effectiveness in the UK. *J R Soc Med* 2003; 96(11): 525–31

## Dermatology

Barker J, Gillard S. Modelling the cost of methotrexate and cyclosporin treatment in psoriasis. 13th European Academy of Dermatology and Venereology Congress 2004

Gillard SE, Finlay AY. Current management of psoriasis in the United Kingdom: patterns of prescribing and resource use in primary care. *Int J Clin Pract* 2005; 59(11): 1260–7

Gillard S, Finlay A, Niziol CJ. Pharmaco-epidemiological analysis of 6,120 psoriasis patients in the United Kingdom. 9th International Congress of the International Society of Dermatology 2004

Humphrey KM, Cork MJ, Haycox A. A retrospective cost-effectiveness analysis of the treatment of onychomycosis in general practice. *Br J Dermatol* 1998; 139(4): 660–4

O'Donnell RA, Finlay AY, Niziol C. The impact of psoriasis on productivity; a survey of psoriasis patients in the United Kingdom. European Congress of Psoriasis 2004: P043

Stratton RJ, Ek AC, Engfer M, Moore Z, Rigby P, Wolfe R., et al. Enteral nutritional support in prevention and treatment of pressure ulcers: A systematic review and meta-analysis. *Ageing Res Rev* 2005; 4: 422–50

## Endocrinology

Bech PG, Buckland AG, Bentley A, Twena N, Christensen TL. Cost-effectiveness of somatropin (Norditropin®) for the treatment of growth hormone deficient (GHD) children in a Swedish setting. Presented at the ISPOR 11th Annual European Congress, Athens, Greece; 8-11 November. 2008.

Bottomley J, Duggan AK, Williams R. Health care needs diabetes model – description of a practical tool. *Pract Diab Int* 2002; 19(7): 206–10

Christensen TL, Buckland AG, Bentley A, Djuurhas C, Twena N. Economic evaluation of somatropin (Norditropin®) for the treatment of short children born small for gestational age (SGA) in Sweden. Presented at the 4th International Congress of the GRS and the IGF Society, Genova, Italy; 16-20 September. 2008

Christensen TL, Buckland AG, Bentley A, Djurhuus CB, Wing C. Economic evaluation of somatropin (Norditropin®) for the treatment of short children born small for gestational age (SGA). Presented at the ISPOR 13th Annual International Congress, Toronto, Canada; 3-7 May. 2008

## 6 | Publications

Christensen TL, Buckland AG, Bentley A, Twena N, Bech PG. Cost-effectiveness of somatropin (Norditropin®) for the treatment of growth hormone deficient (GHD) children in a UK setting. Presented at the ISPOR 11th Annual European Congress, Athens, Greece; 8-11 November. 2008.

Christensen T, Fidler C, Bentley A, Djurhuus C. The cost-effectiveness of somatropin treatment for short children born small for gestational age (SGA) and children with growth hormone deficiency (GHD) in Sweden. *J Med Econ.* 2010 Mar;13(1):168-78.

Elia M, Ceriello A, Laube H, Sinclair A, Engfer M, Stratton R. Enteral nutritional support and use of diabetes-specific formulae for patients with diabetes mellitus: a systematic review and meta-analysis. *Diabetes Care* 2005; 28(9): 2267–79

Twena N, Christensen T, Buckland A, Bentley A, Djurhuus CB. Economic evaluation of somatropin (Norditropin®) for the treatment of short children born SGA in Sweden. *Growth Hormone & IGF Research*, 2008. 18(Supplement 1): p. S39.

### Fracture related

Alt V, Donell ST, Chhabra A, Bentley A, Eicher A, Schnettler R. A health economic analysis of the use of rhBMP-2 in Gustilo-Anderson grade III open tibial fractures for the UK, Germany, and France. *Injury.* 2009 Jun 18

### Gastroenterology

Buckland A, Bodger K. The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis. *Aliment Pharmacol Ther*, 2008.

Duggan AK. Modelling different approaches to the management of upper gastrointestinal disease. *Pharmacoeconomics* 1998; 14 (Suppl 2): 25–37

Duggan AK. The cost of constipation in morphine patients and the economic possibilities with tramadol. *Br J Med Econ* 1995; 9: 21–9

Elia M, Engfer MB, Green CJ, Silk DB. Systematic review and meta-analysis: the clinical and physiological effects of fibre-containing enteral formulae. *Aliment Pharmacol Ther* 2008; 27(2): 120-45.

Haycox A, Howard SP, Partridge A, Wright T. A comparison of evidence and practice in the treatment of constipation. *J Med Econ* 2001; 4: 91–8

### General Medicine

Duggan AK. The cost of analgesia for moderate to severe pain in General Practice. *Br J Med Econ* 1995; 9: 99–106.

Duggan AK. Pharmacoeconomic aspects of the use of tramadol hydrochloride. *Rev Contemp Pharmacother* 1995; 6(10): 541–5

## Geriatrics

Duggan AK, Dakin HA, Jackson DL. An updated Markov model evaluating donepezil: interim results. *Age Ageing* 2003; 32 (Suppl 2): ii43

## Haematology

Dolan G, Smith LA, Collins S, Plumb JM. Effect of setting, monitoring intensity and patient experience on anticoagulation control: a systematic review and metaanalysis of the literature. *Current Medical Research and Opinion*. 2008;24(5):459–1472.

Riedler GF, Dakin HA. “Serious hazards of transfusion” underestimates the incidence of transfusion-related acute lung injury in the UK. *Vox Sang* 2004; 86(4): 268

Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. *Vox Sanguinis* 2003; 85: 88–95

Riedler GF, Haycox AR, Duggan AK, Dakin HA. Impact of TRALI on the cost-effectiveness of solvent-detergent-treated fresh-frozen plasma (Octaplas). *Br J Haematol* 2003; 121 (Suppl 1): 81

Riedler GF, Haycox AR, Duggan AK, Dakin HA. Solvent-detergent-treated plasma may be cost-effective. *Vox Sanguinis* 2003; 84(4): 331–8

## Hepatology

Dakin H, James ES. Results of a mixed treatment comparison meta-analysis of nucleoside and nucleotide therapies for HBeAg-positive chronic hepatitis B. Poster presentation at EASL, April 2008, Milan. 2008.

Dakin H, Barwell T, Sherman M, Yoshida E, Gudaitis E, Canestraro B, et al., editors. Cost-effectiveness of adding in adefovir following clinical or virologic resistance in chronic hepatitis B (CHB) patients. *Canadian Digestive Disease Week (CDDW) and Fourth Annual CASL Winter meeting; 2008; Canada.*

Dusheiko G, Mutimer D, Dakin H, Hughes N. Cost-effective strategies in the treatment of chronic hepatitis B (CHB) with adefovir dipivoxil (ADV). *Hepatology* 2005; 42 (Suppl 1): Abstract 992

## Immunology

Giglio N, Gentile A, Lees L, Micone P, Armoni J, Reygrobellet C, et al. Public health and economic benefits of paediatric influenza vaccination programmes in Argentina. Presented at 6th World Congress of the World Society for Pediatric Infectious Disease; 2009.

Hill DJ, Murch SH, Rafferty K, Wallis P, Green CJ. The efficacy of amino acid-based formulas in relieving the symptoms of cow's milk allergy: a systematic review. *Clin Exp Allergy* 2007; 37(6): 808–22.

## 6 | Publications

### Neurology

Dakin H, Nuijten M, Liedgens H, Nautrup BP. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom. *Clin Ther* 2007; 29(7): 1491-507.

Dakin HA, Nuijten MJC, Liedgens H, Poulsen Nautrup B. Cost-utility analysis evaluating lidocaine 5% medicated plaster relative to gabapentin for post-herpetic neuralgia in Scotland. Podium presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 12th Annual International Meeting, May 19-23 2007, Arlington, Virginia 2007; Presentation NE4

Dakin HA, Nuijten MJC, Poulsen Nautrup B, Liedgens H. Cost-effectiveness of a lidocaine plaster relative to pregabalin in the treatment of post-herpetic neuralgia in Scotland. Podium presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Congress, 20-23 October 2007, Dublin, Ireland 2007; Presentation ND4.

Liedgens H, Hertel N, Gabriel A, et al. Cost-utility analysis evaluating the lidocaine 5% medicated plaster relative to gabapentin and pregabalin for post-herpetic neuralgia in Germany. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Congress, 20-23 October 2007, Dublin, Ireland 2007; Poster PND20

Liedgens H, Hertel N, Gabriel A, et al. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia : a german perspective. . *Clin Drug Investig;* . 2008;28(9):583-601.

Liedgens H, Hertel N, Gabriel A, Nuijten MJC, Dakin HA, Spöhrer U., et al. Cost-effectiveness analysis of the lidocaine 5% medicated plaster relative to gabapentin and pregabalin for post-herpetic neuralgia in Germany. Poster presentation at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 10th Annual European Congress, 20-23 October 2007, Dublin, Ireland 2007; Poster PND13

Ward A, Roberts G, Warner J, Gillard S. Cost-effectiveness of botulinum toxin type a in the treatment of post-stroke spasticity. *J Rehabil Med* 2005; 37(4): 252–7

### Obstetrics

Harrison L. A survey measuring the impact of NICE Guideline 11: Fertility – assessment and treatment for people with fertility problems. Survey One: PCT Commissioning Managers. Abacus International Survey, October 2005 ([www.nice.org.uk](http://www.nice.org.uk)) 2005.

Harrison L. A survey measuring the impact of NICE Guideline 11: Fertility – assessment and treatment for people with fertility problems. Survey Two: Fertility Experts. Abacus International Survey, October 2005 ([www.nice.org.uk](http://www.nice.org.uk)) 2005

## Oncology

Elia M, Van Bokhorst-de van der Schueren MA, Garvey J, Goedhart A, Lundholm K, Nitenberg G., et al. Enteral (oral or tube administration) nutritional support and eicosapentaenoic acid in patients with cancer: a systematic review. *Int J Oncol* 2006; 28(1): 5–23

Graham J, Murray B, Dakin H, Warner J. Cost of advanced renal cell carcinoma (RCC) in the UK. 2nd National Cancer Research Institute Cancer Conference, 8–11 October 2006, Birmingham UK 2006

Hopper C, Niziol C, Sidhu M. The cost-effectiveness of Foscan mediated photodynamic therapy (Foscan-PDT) compared with extensive palliative surgery and palliative chemotherapy for patients with advanced head and neck cancer in the UK. *Oral Oncol* 2004; 40(4): 372–82

Kubler A, Niziol C, Sidhu M, Dunne A, Werner JA. [Analysis of cost effectiveness of photodynamic therapy with Foscan (Foscan-PDT) in comparison with palliative chemotherapy in patients with advanced head-neck tumors in Germany]. *Laryngorhinootologie* 2005; 84(10): 725-32

## Ophthalmology

Roberts G, Buchholz P, Holmstrom S, Finck K, Gillard S, Warner J., et al. Comparison of the clinical and cost effectiveness of Lumigan and Xalatan, in the treatment of glaucoma. *Value Health* 2003; 6(6): PAE10

Orme M, Collins S, Dakin H, Loftus J. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. *Current Medical Research & Opinion*. 2010;26(3):511-28.

Orme M, Loftus J, Collin S, editors. Modelling the long-term clinical outcomes of medical management of primary open angle glaucoma and ocular hypertension; 2008.

Orme M, Loftus J, Collin S, Kelly S, editors. A mixed treatment comparison of topical and ocular hypertensives for the treatment of glaucoma and ocular hypertension; 2008.

## Orthopaedics

Buckland AG PJ. Cost-Effectiveness of Hip Resurfacing in Younger Adults in the United States. *Journal of Managed Care Medicine* 2008;11(4):25-32.

Richardson JB, Band T, Barnes DC, Buckland AG, Posnett J. Metal on metal (MoM) hip resurfacing (Birmingham Hip Resurfacing [BHR]) in young patients with severe hip damage - A cost utility analysis. *Value in Health* 2005; 8(6): A24 (Abstract PAR2)

## 6 | Publications

### Pain

Choy E, Marshall D, Gabriel Z, Mitchell S, Gylee E, Dakin H. A systematic review and mixed treatment comparison (MTC) of the efficacy of pharmacological treatments for fibromyalgia. Presented at ISPOR 12th Annual European conference. 2009

### Psychiatric

Dakin HA, Sidhu M. Cost-effectiveness of clozapine to prevent suicide in schizophrenia: interim results. *J Psychopharmacol* 2003; 17(3 (suppl)): A54 (abstract E48).

Duggan AK, Munro J. Should Clozaril be used early or late in treatment pathways – a health economic perspective. 'The eariler use of Clozaril: a discussion' 2001

Duggan A, Warner J, Knapp M, Kerwin R. Modelling the impact of clozapine on suicide in patients with treatment-resistant schizohprenia in the UK. *Br J Psychiatry* 2003; 182: 505–8

Lockhart I, Mitchell S, Kelly S, editors. A systematic review of the real-world study evidence comparing the safety and tolerability of donepezil, rivastigmine, galantamine for the treatment of mild to moderate Alzheimer's disease. . Presented at ISPOR 12th Annual European conference; 2009.

Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. *Dement Geriatr Cogn Disord*. 2009;28(5):389-403.

### Respiratory


Duerden M, Walley T, Mitchell G, Niziol C. Rates of transition up the British Asthma Guidelines steps of care in UK general practice. 22nd European Academy of Allergy and Clinical Immunology Congress 2003

Haughney J, Grishchenko M, Dakin HA, Ballabio M, Caputo G. Cost-effectiveness of erdosteine in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD). *Thorax* 2007; 62(Suppl III): A47

Haycox A, Mitchell G, Niziol C, Featherstone R. Cost effectiveness of asthma treatment with a breath-actuated pressurised metered dose inhaler (BAI) – a prescribing claims study of 1,856 patients using a traditional pressurised metered dose inhaler (MDI) or a breath-actuated device. *J Med Econ* 2002; 5: 65–77.

Niziol C. Respiratory care in community settings. *Nurs Stand* 2004; 19(4): 41–5.

Price D, Mitchell G, Niziol C. Breath activated inhaler usage and impact on rescue medication usage in patients with an asthma diagnosis: A prescribing claims study of 7,412 patients using a CFC-MDI or a breath-actuated device. 13th European Respiratory Society Annual Congress 2001



Price D, Thomas M, Mitchell G, Niziol C, Featherstone R. Improvement of asthma control with a breath-actuated pressurised metered dose inhaler (BAI): A prescribing claims study of 5,556 patients using a traditional pressurised metered dose inhaler (MDI) or a breath actuated device. *Respiratory Medicine* 2003; 97: 12–19.

Thomas M, Price D, Mitchell G, Niziol C. Asthma control with a breath-actuated pressurised metered dose inhaler (BAI) and prevalence of oral candidiasis: A prescribing claims study of 1,701 patients prescribed a traditional pressurised metered dose inhaler (MDI) plus spacer or a BAI. 12th European Respiratory Society Annual Congress 2002

## Surgery

Barwell T. A survey measuring the impact of NICE Clinical Guideline 3: The use of routine preoperative tests for elective surgery. Abacus International Survey, September 2005 ([www.nice.org.uk](http://www.nice.org.uk)) 2005

Duggan AK. The cost of managing post-operative pain with intravenous tramadol compared with epidural morphine. *Br J Med Econ* 1995; 9: 37–40

Duggan AK. The cost of managing post-operative pain: a comparison of tramadol and morphine. *Br J Med Econ* 1995; 9: 59–66

Howard S. A survey measuring the impact of NICE guidance 24: The use of debriding agents and specialist wound care clinics for difficult to heal surgical wounds. Abacus International Survey ([www.nice.org.uk](http://www.nice.org.uk)) 2004

## Urology

Cardoza L, Thorpe A, Grishenko M, MK S, editors. A cost utility analysis of solifenacin 5 mg and solifenacin 10 mg versus tolterodine ER in the pharmacological treatment of patients with OAB in the UK NHS.

Cardoza L, Thorpe A, Grishenko M, MK S, editors. A cost utility analysis of solifenacin 5 mg and solifenacin 10 mg versus tolterodine ER in the pharmacological treatment of patients with OAB.

Haycox A, Duggan AK. Optimising the future development of dialysis services in the UK. *Br J Med Econ* 1996; 10: 15–35

Kalsi V, Popat RB, Apostolidis A, Kavia R, Odeyemi IA, Dakin HA, et al., Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre. *Eur Urol* 2006; 49(3): 519–27

Krupa BS, Duggan AK, Haycox A. Costing renal service provision – the Shrewsbury Renal Revenue Model. *Br J Med Econ* 1996; 10: 15–26

## 6 | Publications

Odeyemi IAO, Dakin HA, O'Donnell RA, Warner J, Jacobs A, Dasgupta P. Epidemiology, prescribing patterns and resource use associated with overactive bladder in UK primary care. *Int J Clin Pract* 2006; 60(8): 949–58

Stratton R, Bircher G, Fouque D. Multi-nutrient oral supplements and tube feeding in maintenance dialysis: a systematic review and meta-analysis. *Am J Kid Dis* 2005; 46(3): 387–405

### Other

Dakin HA, Devlin NJ, Odeyemi IA. “Yes”, “No” or “Yes, but”? Multinomial modelling of NICE decision-making. *Health Policy* 2006; 77(3): 352–67

Devlin N, Parkin D, Dakin H. NICE decision making in the UK: new evidence on the influence of cost effectiveness, quality of evidence and uncertainty. 5th World Congress of the International Health Economics Association, Barcelona 2005

Howard S. Measuring the impact of NICE guidance across 28 disease areas. In: *Clinical Excellence 2004 NICE conference publication*. London: NICE; 2004. p. 110–8.

Howard S, Harrison L. NICE guidance implementation tracking: data sources, methodology and results. Bicester: Abacus International; 2004.

McAllister R, Harrison L, Niziol C. Shared Risk. *European BioPharmaceutical Review*. 2009.

Niziol C. Myth busting. *Nurs Stand* 2005; 19(42): 70–1.

O'Donnell R, Niziol C. 10 ways to maximise the potential of your HTA submission: a practical guide. *Pharmaceutical Marketing* 2006

### Directors

Simon Howard, **Managing Director**

+44 (0) 1869 357222

[simon.howard@abacusint.com](mailto:simon.howard@abacusint.com)

Tony Barwell, **Director**

+44 (0) 1869 357224

[tony.barwell@abacusint.com](mailto:tony.barwell@abacusint.com)

### Senior staff

Sarah Collins, **Associate Director - Systematic Review**

+44 (0) 1869 241281

[sarah.collins@abacusint.com](mailto:sarah.collins@abacusint.com)

Linda Harrison, **Associate Director - HTA**

+44 (0) 1869 357229

[linda.harrison@abacusint.com](mailto:linda.harrison@abacusint.com)

Christie Harper, **Consultant - HTA Tracking**

+44 (0) 1869 241281

[christie.harper@abacusint.com](mailto:christie.harper@abacusint.com)

Juliet Warner, **Associate Director - Health Economics**

+44 (0) 1869 357220

[juliet.warner@abacusint.com](mailto:juliet.warner@abacusint.com)

May 2010

bright minds, brilliant outcomes

Abacus International UK | 4 Market Square | Bicester | Oxfordshire | OX26 6AA | United Kingdom  
T: +44 (0)1869 241281 | F: +44 (0)1869 323248 | [www.abacusint.com](http://www.abacusint.com)  
Registered in the UK No. 3034965